Latest Hygiene hypothesis Stories
DIEPENBEEK, Belgium, September 4, 2014 /PRNewswire/ -- Scientists discover how to 'switch off' autoimmune diseases Apitope, the drug discovery
A number of studies suggest that children delivered by Caesarean section have a different intestinal flora than children delivered by natural birth.
The greater prevalence of asthma, allergies and other chronic inflammatory disorders among people of lower socioeconomic status might be due in part to their reduced exposure to the microbes that thrive in rural environments
Good hygiene typically leads to good health, but new research appearing in the journal Evolution, Medicine and Public Health suggests that people living in industrialized nations could be more likely to develop Alzheimer’s disease due to cleanliness.
In a new study of nearly 80,000 children, researchers have found foreign-born US children have significantly fewer allergies than those born in the US. However, this lower allergy risk begins to dissipate after these children have been in America for ten years.
Neurons that control hunger in the central nervous system also regulate immune cell functions, implicating eating behavior as a defense against infections and autoimmune disease development.
Over the previous several years, medical professionals have noted and documented marked increases in the prevalence of autoimmune diseases. An international team of scientists and researchers have come together in an attempt to identify the cause behind the increase in such diseases.
For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two.
Childhood exposure to bacteria and other germs may help build immunity to various microbes later on in life, researchers from Brigham and Women's Hospital (BWH) claim in a new study.
NEW YORK, July 6, 2011 /PRNewswire/ -- Coronado Biosciences, a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer, today announced that it closed a $25.8 million Series C financing led by National Securities Corporation.